Related Experiment Video
Updated: Aug 14, 2025

Probiotic Studies in Neonatal Mice Using Gavage
Published on: January 27, 2019
Probiotics for prevention of necrotizing enterocolitis: Where do we stand?
Maria Estefania Barbian1, Ravi Mangal Patel1
1Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, 2015 Uppergate Dr. NE, Atlanta, GA 30322, United States.
This review examines the history and current evidence for probiotics in preterm infants, focusing on their effects on necrotizing enterocolitis, sepsis, and mortality. It discusses guidelines and real-world experiences to understand routine use complexities.
Area of Science:
- Neonatal Medicine
- Microbiology
- Clinical Research
Background:
- Probiotics are increasingly considered for preterm infants to prevent common morbidities.
- Necrotizing enterocolitis, sepsis, and mortality remain significant concerns in this vulnerable population.
Approach:
- This review synthesizes historical data and recent evidence from randomized trials and cohort studies.
- It analyzes professional society guidelines and real-world data from North American centers.
Key Points:
- Evidence supports probiotics' potential to reduce necrotizing enterocolitis, sepsis, and mortality in preterm infants.
- Guidance statements offer recommendations, but interpretation requires careful consideration of study quality and context.
- Routine use involves practical considerations and complexities observed across multiple clinical settings.
Conclusions:
- Probiotic use in preterm infants is evolving, with growing evidence supporting benefits.
- Balancing evidence, guidelines, and clinical experience is crucial for optimizing their application.
- Further research and standardized reporting are needed to fully elucidate the role of probiotics.
More Related Videos
Related Concept Videos
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...

